NexusGen flagship programme
Decoding kidney disease progression in Ghana.
A Ghana-led longitudinal discovery platform integrating clinical phenotyping, genomics, biomarkers, vascular and retinal imaging, environmental exposures and AI-enabled risk prediction.
Explore the programmeRESEARCH TRANSPARENCY
Planned scale, clearly labelled.
This page describes the intended scientific design and platform scale. The figures shown are design targets, not a statement of participants already enrolled.
Scientific and operational development is presented transparently as the platform progresses.
“Up to 10,000” and “≈1,000” describe intended cohort architecture rather than completed recruitment.
Approved recruitment information and participant materials will be made available through the appropriate study channels.
This is not a clinical-data portal. Do not send patient records, participant information or medical details through the public enquiry form.
INTEGRATED DISCOVERY
One participant. Multiple layers of evidence.
Clinical measures are connected with biological, genomic, imaging, exposure and digital data to examine why kidney disease follows different trajectories.
01 · THE SCIENTIFIC QUESTION
Why do some people progress rapidly while others remain stable?
Similar clinical measurements can conceal very different biological pathways, inherited risks and environmental influences.
NexusGen CKD is designed to identify those differences, connect them with longitudinal kidney and cardiovascular outcomes, and test whether they improve prediction beyond established clinical factors.
02 · INTEGRATED PHENOTYPING
Multiple evidence layers around every participant.
The design combines broad cohort scale with a nested subgroup characterised in greater biological and mechanistic depth.
ACTIVE LAYER · DNA
Genomics and APOL1
Tests how genetic variation modifies kidney decline, cardiovascular risk and biological pathways.
03 · COHORT ARCHITECTURE
Scale for outcomes. Depth for mechanisms.
Every participant contributes to the core longitudinal framework; selected groups contribute richer imaging, biological, environmental and digital measurements.
SELECTED COHORT LAYERUp to 10,000
Core cohort
The full longitudinal platform captures clinical phenotype, care pathways and kidney, cardiovascular and mortality outcomes.
01Kidney function and albuminuria
02Kidney failure and treatment pathways
03Cardiovascular events and mortality
04 · PLATFORM VALUE
Discovery designed for translation.
Fast-progressor signatures
Clinical and biological combinations associated with rapid decline.
Ghana-relevant prediction
Models assessed for discrimination, calibration and subgroup performance.
Trial-ready resource
A longitudinal cohort and biobank prepared for future intervention research.
05 · SPECIALIST SUPPORT
Scientific and technology contributions.
Contributions strengthen specific platform components while research direction, analysis and interpretation remain independent.
Nordic Bioscience
In-kind PRO-C6 and C3M analysis for extracellular-matrix and fibrosis biology.
Activinsights
Wearable monitoring support for activity, sleep and daily behavioural patterns.
B Medical Systems
Medical-grade sample storage and cold-chain infrastructure support.